Skip to content

A Real World Study on Shexiang Baoxin Pill in Relieving Anxiety and Depression in Patients with Coronary Heart Disease after PCI by Application of 'Double Heart Care' Concept

A Real World Study on Shexiang Baoxin Pill in Relieving Anxiety and Depression in Patients with Coronary Heart Disease after PCI by Application of 'Double Heart Care' Concept

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041451
Enrollment
Unknown
Registered
2020-12-26
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease complicated with anxiety and depression

Interventions

Sponsors

The First Affiliated Hospital of Suzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years or above, regardless of gender; 2. Patients who complained of chest tightness and chest pain and were definitely diagnosed as coronary heart disease; 3. Patients who have received standardized treatment (coronary artery disease drugs, according to the needs of the patient's condition, coronary intervention treatment); 4. All the patients were assessed with the symptom Checklist-90 (SAS), depression scale (SDS), self-efficacy and quality of life scale (SF-36) to confirm that the patients had mild anxiety and depression; the patients with SAS score of 50-59 and or SDS score of 50-60 were included; 5. Patients who voluntarily sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients whose expected survival time is less than 12 months; 2. Patients with previous psychiatric history or severe depression or suicidal tendency; 3. Patients with severe cerebrovascular disease in recent 6 months; 4. Patients with malignant arrhythmias such as ventricular tachycardia, ventricular flutter and ventricular fibrillation; 5. Patients with severe cardiac insufficiency were classified as grade IV; 6. Women of childbearing age, pregnancy or lactation, or those who intend to give birth within one year; 7. Patients with serious uncontrolled respiratory, digestive, kidney, blood, infection, immune, endocrine, tumor diseases or diseases that may cause serious risk to patients; 8. Patients with morphine, alcohol and other substance abuse or dependence in recent 6 months; 9. Patients allergic to Shexiang Baoxin Pills.

Design outcomes

Primary

MeasureTime frame
the scores of anxiety;the scores of depression;the score of SF-36;adverse events;6-minute walk test;Echocardiographic data;NYHA grade;

Countries

China

Contacts

Public ContactXu Mingzhu

The First Affiliated Hospital of Suzhou University

lilac83@163.com+86 15050490317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026